DENVER, Colo., Dec 30, 2024 (247marketnews.com)- Autonomix Medical (NASDAQ: AMIX) stated that the United States Patent and Trademark Office (USPTO) issued U.S. patent 12,064,256 (‘256 patent) titled, Systems and Methods for Treating Cancer and/or Augmenting Organ Function, to the Company, covering technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain, which Autonomix is initially advancing the development of its technology to address pancreatic cancer-related pain.
Brad Hauser, CEO of Autonomix, commented, “As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority.
“Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”
Autonomix’s catheter-based sensing technology is covered by over 80 issued patents and over 40 pending patent applications, globally.
The post Autonomix Medical Awarded U.S. Patent Covering Cancerous Tumors Treatment and Cancer Related Pain with Company’s Catheter-Based Technology appeared first on 24/7 MarketNews.
